Zealand Pharma Petrelintide Cuts 9.2% Body Weight in Phase 2

Zealand Pharma A/S announced on 7 October 2026 that its once-weekly amylin analog petrelintide met the primary endpoint of the Phase 2 ZUPREME-2 trial, producing up to 9.2% mean body weight reduction at week 28 versus 2.0% for placebo in 220 adults with overweight or obesity and type 2 diabetes. The company reported a placebo-adjusted HbA1c reduction of 0.61%-0.88% and gastrointestinal adverse-event discontinuation of 1.9% versus 1.7% on placebo.

Context — why ZUPREME-2 matters now

The report frames ZUPREME-2 as the second readout for petrelintide, following the 42-week Phase 2 ZUPREME-1 trial in people with overweight or obesity without type 2 diabetes. The company said the safety and tolerability profile seen in ZUPREME-2 confirms what ZUPREME-1 showed, giving the program a repeatable tolerability signal across two distinct patient populations.

The trial enrolled a mean baseline BMI of 36.3 kg/m2 and a mean baseline HbA1c of 8.0%, a cohort with both a weight and a glycemic problem rather than weight alone. That matters because the company is positioning petrelintide as a possible first-choice therapy for chronic weight management, a claim that requires efficacy in patients whose diabetes complicates the picture.

Participants were on metformin with or without an SGLT2 inhibitor, so the glycemic result was achieved on top of existing oral therapy rather than in treatment-naive patients. The company said petrelintide is being developed as a monotherapy and in combination with Roche's GLP-1/GIP dual agonist enicepatide (CT-388).

Zealand Pharma and Roche have already started the Phase 3a program, which the company said consists of three trials expected to enroll approximately 7,000 participants in total. The first individuals have initiated treatment, so the readout window for registrational data is now running.

Data — what the numbers show

The efficacy estimand showed weight loss ranging from 7.4% to 9.2% across the three petrelintide arms, against 2.0% for placebo. The company said results remained largely consistent under the treatment regimen estimand, which addresses whether the effect survives how patients actually took the drug.

Endpoint at week 28	Petrelintide	Placebo
Mean weight loss (efficacy estimand)	7.4%-9.2%	2.0%
HbA1c change	reduction up to 0.65%	increase of 0.23%
GI AE discontinuation	1.9%	1.7%

Secondary endpoints in ZUPREME-2 include body weight loss of at least 5% and at least 10%, absolute change in body weight, waist circumference, hsCRP, fasting glucose and fasting lipids. The company did not disclose topline values for those secondary endpoints in this announcement.

ZUPREME-2 was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, US-based Phase 2b trial registered as NCT06926842. Dosing escalated every fourth week for up to 16 weeks, followed by maintenance until week 28 and follow-up to week 38. The report gives no market-level comparison for the trial data.

Analysis — what it means for markets and sectors

Petrelintide sits in the amylin analog class, which the report describes as working by restoring sensitivity to the satiety hormone leptin. That mechanism is distinct from GLP-1 receptor agonism, and the company is explicitly pairing it with Roche's GLP-1/GIP dual agonist rather than treating the two as substitutes. The combination Phase 2 trial is planned for initiation in the second half of 2026, per the report.

The disclosed GI discontinuation rate of 1.9% is the number obesity-drug investors will weigh most heavily, because tolerability has been the commercial constraint across the incretin class. A rate essentially indistinguishable from placebo, sustained across ZUPREME-1 and ZUPREME-2, supports the company's claim that petrelintide could be a first-choice chronic weight management therapy.

The counter-argument is that ZUPREME-2 enrolled 220 participants over 28 weeks. That is a small, short window relative to the Phase 3a program's approximately 7,000 participants across ZUPREME-3, ZUPREME-4 and ZUPREME-5, which will test obesity without diabetes, obesity with diabetes, and obesity with established cardiovascular disease respectively. Longer exposure and larger cohorts are where tolerability and efficacy signals can shift.

Positioning in the amylin space has been building around the assumption that a better-tolerated agent can take share from GLP-1 monotherapies. This readout supports that thesis without proving it, because the trial had no active GLP-1 comparator arm.

Outlook — what to watch next

Three catalysts sit on the calendar. Full ZUPREME-2 results are expected at an upcoming scientific conference, which the company did not date. The petrelintide and enicepatide combination Phase 2 trial is planned for initiation in the second half of 2026. And the Phase 3a program, covering ZUPREME-3, ZUPREME-4 and ZUPREME-5, has begun dosing.

The report gives no price levels, so there are none to watch. The variables that matter are the full secondary-endpoint data, including the at-least-5% and at-least-10% weight loss responder rates, and whether the Phase 3 trials reproduce the GI discontinuation rate near placebo. Zealand Pharma trades on Nasdaq under ZEAL.

Frequently Asked Questions

What does the ZUPREME-2 result mean for retail investors in Zealand Pharma?

It is a clinical readout, not a financial result. The company reported that petrelintide met its primary endpoint with up to 9.2% mean weight loss and a GI discontinuation rate of 1.9% versus 1.7% for placebo. Any investment case rests on whether the ongoing Phase 3a program, expected to enroll roughly 7,000 participants, reproduces those numbers in larger and longer trials.

What happens next for petrelintide?

The company said full ZUPREME-2 results will be presented at an upcoming scientific conference, without giving a date. A Phase 2 trial of petrelintide combined with Roche's enicepatide is planned to start in the second half of 2026. The Phase 3a program of ZUPREME-3, ZUPREME-4 and ZUPREME-5 has begun, with the first participants dosed.

Why did HbA1c fall in the petrelintide arms but rise on placebo?

Participants had a mean baseline HbA1c of 8.0% and were on metformin with or without an SGLT2 inhibitor. Petrelintide produced a reduction of up to 0.65%, while the placebo group saw a 0.23% increase. The company framed the glycemic improvement as complementary to weight loss for long-term benefit in people with obesity and type 2 diabetes.

Bottom Line

Petrelintide hit its Phase 2 weight and glycemic endpoints with placebo-like GI tolerability, shifting the burden of proof to the 7,000-participant Phase 3a program.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.